Celgene(NASDAQ: CELG) recently reported that its multiple sclerosis drug, ozanimod, successfully met its endpoints in reducing multiple sclerosis (MS) relapses, and assuming a second trial pans out ...
A new and highly anticipated study byCelgene Corp. (NASDAQ: CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management ...
Neomorph, Inc., a biotechnology company advancing a new class of molecular glue degraders to target historically undruggable ...
Celgene has backed out of a $55 million settlement it reached last year in a move legal experts are calling highly unusual, according to STAT. The class-action lawsuit accused Celgene — which was ...
Celgene has refiled for FDA approval of ozanimod in multiple sclerosis. The resubmission comes one year after Celgene was rocked by a refusal-to-file notice from the FDA. The FDA hit Celgene with the ...
(Reuters) - Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc ...
REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results